Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Updated newborn screening guidelines aim to improve cystic fibrosis detection

1

Feb 2026

Updated newborn screening guidelines aim to improve cystic fibrosis detection

An updated report on cystic fibrosis (CF) from Ann & Robert H. Lurie Children's Hospital of Chicago, in partnership with the Cystic Fibrosis Foundation and funded by the Centers for Disease Control and Prevention (CDC), highlights the new national guidelines on CF newborn screening that aim to detect affected babies earlier, more accurately and more fairly.

Age shapes long-term outcomes after multi-arterial CABG strategies

31

Jan 2026

Age shapes long-term outcomes after multi-arterial CABG strategies

A late-breaking study drawing on more than 15 years of national outcomes data from the STS Adult Cardiac Surgery Database (ACSD) suggests that the two most commonly used multi-arterial coronary artery bypass grafting (CABG) strategies-bilateral internal thoracic artery (BITA) and single internal thoracic artery plus radial artery (SITA+RA)-offer comparable long-term survival overall, with important differences emerging by patient age.

New model predicts redo surgery risk in adult congenital heart disease

31

Jan 2026

New model predicts redo surgery risk in adult congenital heart disease

Heart specialists at Mayo Clinic today presented new research at the 2026 Society of Thoracic Surgeons Annual Meeting that redo surgery for adults with congenital heart disease (CHD) remains high-risk, and a clinically applicable national risk assessment model is needed to help patients and care teams make decisions about procedures.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.